Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984093 | 0.86 | GPR4 (0.51) | GPR4EPHX2GPR119HRH2HRH1 | |
| SCHEMBL31269123 | 0.85 | GPR4 (0.51) | GPR4EPHX2GPR119PDE3BPDE3A | |
| SCHEMBL30983866 | 0.85 | KDM4E (0.51) | GPR4EPHX2GPR119KCNA5PDE3B | |
| SCHEMBL30984069 | 0.85 | GPR119 (0.51) | GPR4EPHX2GPR119PDE3BPDE3A | |
| SCHEMBL31268813 | 0.84 | DRD3 (0.53) | GPR4EPHX2GPR119PDE3BPDE3A | |
| SCHEMBL1673377 | 0.80 | GPR4 (0.53) | GPR4EPHX2GPR119HRH2HRH1 | |
| SCHEMBL7251887 | 0.79 | HRH2 (0.52) | EPHX2GPR119HRH2HRH1HRH3 | |
| SCHEMBL3581553 | 0.78 | TLR9 (0.49) | EPHX2GPR119HRH2HRH1HRH3 | |
| SCHEMBL7245807 | 0.77 | HRH2 (0.71) | EPHX2GPR119HRH2HRH1HRH3 | |
| SCHEMBL216291 | 0.77 | EPHX2 (0.52) | GPR4EPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |